• Clinical updates on BK polyomavirus in kidney transplantation

  • Clinical updates on BK polyomavirus in kidney transplantation

  • Clinical updates on BK polyomavirus in kidney transplantation

  • Clinical updates on BK polyomavirus in kidney transplantation

#Infection #Oceania

Live Session:

Wednesday, June 23, 2021 - 5:00 PM (Local time in Sydney)
Local time (Corresponding time at your current location)

Join us:



This masterclass will discuss the most up-to-date knowledge on the epidemiology, clinical presentation, and immune responses to Polyomavirus infection in kidney transplant recipients. Recent data on the potential therapies for Polyomaviruses in kidney transplantation will also be presented.

Learning Objectives:

  • Understand the immunology, epidemiology, and clinical presentation of polyomavirus in kidney transplant recipients

  • Learn the latest advances in screening, detection, and treatment strategies of polyomavirus in kidney transplant recipients


BK polyomavirus: clinical aspects and immune regulation

Hans Hirsch

Director of the Clinical Virology Diagnostic Laboratory 
University of Basel
Consultant Infectious Diseases & Hospital Epidemiology
University Hospital Basel
Basel, Switzerland

Hans H. Hirsch, MD, MSc, studied medicine at the Albert-Ludwigs-University in Freiburg (Germany) and biochemistry at Oregon State University in Corvallis (OR, USA). He then specialized in internal medicine, infectious diseases, and medical microbiology at the University of Basel and the University Hospital Basel. In 2004, the Medical Faculty of the University of Basel appointed him as Professor for Medical Microbiology. Currently, Dr.  Hirsch is the director of the Clinical Virology diagnostic laboratory and holds a senior clinical appointment as a consultant in Infectious Diseases at the University Hospital Basel. Dr. Hirsch heads the research group “Transplantation & Clinical Virology” at the Department of Biomedicine of the University of Basel. Dr. Hirsch has a special interest in virus infections and immunocompromised patients, including transplant and HIV patients, and is a member of the Swiss HIV Cohort Study, the Swiss Transplant Cohort Study. Dr. Hirsch was engaged as TTS-Transplant Infectious Disease Councilor for Africa-Europe-Middle East (2015 – 2017) and is Fellow of European Society Clinical Microbiology & Infectious Diseases (ESCMID), Fellow of the American Society of Transplantation (FAST), and the current president of the International Immunocompromised Host Society (ICHS).

BK polyomavirus: emerging therapies

Brian Nankivell

Transplant Physician, Dept Renal Medicine
Westmead Hospital
Sydney, Australia

Dr. Nankivell is currently a practicing nephrologist and transplant clinician working at Westmead Hospital and the National Pancreas Transplant Unit in Sydney.

His MBBS was from the University of Sydney. Following his FRACP, specializing in nephrology, an MSc in pharmacology from the University of London, and two doctorates from the University of Sydney were obtained; as a Ph.D. in the mechanisms of progression of chronic renal failure and a higher doctorate MD examining transplant graft dysfunction.

His research interests involve transplant renal function, the structural-functional relationships of failing allografts, renal function estimation, the histopathology of acute and chronic transplant rejection, calcineurin inhibitor nephrotoxicity, BK virus allograft nephropathy, and the Banff schema of diagnostic transplant pathology.


Helen Pilmore

Associate Professor
Auckland University and Auckland City Hospital
Aukland, New Zealand

John Kanelis

Head of Transplantation
Monash Medical Centre
Melbourne, Australia

Schedule (90 min):

  • 05 min

    Welcome and introduction by the Chairs

  • 25 min

    Presentation: BK polyomavirus: clinical aspects and immune regulation, Hans Hirsch, Switzerland

  • 05 min

    Live Q&A with Hans Hirsch, Switzerland

  • 25 min

    Presentation: BK polyomavirus: emerging therapies, Brian Nankivell, Australia

  • 05 min

    Live Q&A with Brian Nankivell, Australia

  • 20 min

    Interactive panel discussion with audience participation led by the Chairs

  • 05 min

    Masterclass closing remarks

Join Our Mailing List

Ask a Question

Masterclass Prospectus Request